Wealth Enhancement Advisory Services LLC Takes $412,000 Position in Roivant Sciences Ltd. $ROIV

Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 19,050 shares of the company’s stock, valued at approximately $412,000.

A number of other institutional investors also recently added to or reduced their stakes in ROIV. Perceptive Advisors LLC bought a new stake in Roivant Sciences during the second quarter valued at about $37,546,000. Marshall Wace LLP boosted its position in Roivant Sciences by 316.5% during the third quarter. Marshall Wace LLP now owns 3,978,001 shares of the company’s stock valued at $60,187,000 after purchasing an additional 3,022,851 shares in the last quarter. Orbimed Advisors LLC bought a new stake in Roivant Sciences during the second quarter valued at about $31,324,000. Rubric Capital Management LP boosted its position in Roivant Sciences by 14.7% during the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after purchasing an additional 2,603,260 shares in the last quarter. Finally, Voloridge Investment Management LLC bought a new stake in Roivant Sciences during the third quarter valued at about $34,513,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $28.21 on Friday. The company has a market cap of $20.19 billion, a PE ratio of -24.11 and a beta of 1.20. The business has a 50-day simple moving average of $27.40 and a two-hundred day simple moving average of $22.69. Roivant Sciences Ltd. has a fifty-two week low of $9.57 and a fifty-two week high of $30.33.

Insiders Place Their Bets

In related news, Director Daniel Allen Gold sold 375,784 shares of Roivant Sciences stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $26.50, for a total transaction of $9,958,276.00. Following the completion of the sale, the director owned 15,127,329 shares of the company’s stock, valued at $400,874,218.50. The trade was a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $28.24, for a total value of $5,648,000.00. Following the sale, the chief executive officer directly owned 1,647,546 shares of the company’s stock, valued at $46,526,699.04. This trade represents a 10.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 4,795,624 shares of company stock valued at $129,232,136. 10.80% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ROIV has been the topic of a number of recent research reports. Citigroup raised their price objective on Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. Guggenheim raised their price objective on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Sanford C. Bernstein initiated coverage on Roivant Sciences in a research report on Friday, March 20th. They set an “outperform” rating and a $35.00 price objective on the stock. Weiss Ratings downgraded Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, February 9th. Finally, Leerink Partners raised their price target on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and an average price target of $29.50.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.